Bibliografías temáticas / Arformoterol / Artículos de revistas
Siga este enlace para ver otros tipos de publicaciones sobre el tema: Arformoterol.

Artículos de revistas sobre el tema "Arformoterol"

Autor: Grafiati
Publicado: 7 de junio de 2025
Última modificación: 2 de agosto de 2025

Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros

Elija tipo de fuente:

Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "Arformoterol".

Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.

También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.

Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.

1

King, Paul T. "Pharmacotherapy of Chronic Obstructive Pulmonary Disease: Focus on Arformoterol Tartrate." Clinical Medicine. Therapeutics 1 (January 2009): CMT.S2584. http://dx.doi.org/10.4137/cmt.s2584.

Texto completo
Resumen
Arformoterol tartrate is a newly developed long-acting ssβ2-agonist with both acute and prolonged bronchodilator effects. It is formed of 2 isomers (R,R/R,R) which distinguishes it from the more commonly used racemic formoterol (R,R/S,S). The active isomer is the (R,R) and in vitro arformoterol may have more potent anti-inflammatory effects than formoterol. It can only be given by a nebulizer. There have been 5 randomized, blinded trials which have assessed the use of arformoterol in chronic obstructive pulmonary disease (COPD). Arformoterol has been demonstrated to improve lung function and s
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

&NA;. "Arformoterol." Drugs in R & D 5, no. 1 (2004): 25–27. http://dx.doi.org/10.2165/00126839-200405010-00004.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

Hazra, Moumita. "A pharmacoepidemiological study of prescription patterns of β2 sympathomimetic bronchodilators in exacerbation of non-severe asthma in tertiary care hospitals, not needing hospitalization". International Journal of Basic & Clinical Pharmacology 8, № 12 (2019): 2674. http://dx.doi.org/10.18203/2319-2003.ijbcp20195276.

Texto completo
Resumen
Background: Arformoterol, the (R, R) enantiomer of the racemic (R, R / S, S) diastereomer, formoterol, is a short and long acting β2 agonist bronchodilator. Levosalbutamol, the (R, R) enantiomer of racemic diastereomer (R, R / S, S) salbutamol, has a greater affinity for the β2 receptor. Occupation of β2 receptors by agonists result in the activation of the Gs-adenylyl cyclase-cAMP-PKA pathway, followed by phosphorylative events leading to bronchial smooth muscle relaxation. The aim of this pharmacoepidemiological study was to analyse the prescription patterns, and prescription content analysi
Los estilos APA, Harvard, Vancouver, ISO, etc.
4

Cada, Dennis J., Terri Levien, and Danial E. Baker. "Arformoterol Tartrate." Hospital Pharmacy 42, no. 5 (2007): 447–54. http://dx.doi.org/10.1310/hpj4205-447.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
5

Revill, P., N. Serradell, J. Bolós, and M. Bayés. "Arformoterol Tartrate." Drugs of the Future 31, no. 11 (2006): 944. http://dx.doi.org/10.1358/dof.2006.031.11.1047743.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
6

&NA;. "Arformoterol comparable to salmeterol for COPD." Inpharma Weekly &NA;, no. 1558 (2006): 6. http://dx.doi.org/10.2165/00128413-200615580-00013.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
7

Cazzola, Mario, Nicola A. Hanania, and Maria G. Matera. "Arformoterol tartrate in the treatment of COPD." Expert Review of Respiratory Medicine 4, no. 2 (2010): 155–62. http://dx.doi.org/10.1586/ers.10.16.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
8

Bhutnar, Arun, Anita Desai, Sachin Khapare, Sonali Vartak, Ajay Pangavhane, and Allwyn Andrandes. "Identification and Structural Characterization of Secondary Degradant of Arformoterol Impurity in LDPE Respules of Arformoterol Tartrate Inhalation Solution." American Journal of Analytical Chemistry 09, no. 05 (2018): 286–301. http://dx.doi.org/10.4236/ajac.2018.95022.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
9

King, Paul. "Role of arformoterol in the management of COPD." International Journal of Chronic Obstructive Pulmonary Disease Volume 3 (September 2008): 385–91. http://dx.doi.org/10.2147/copd.s753.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
10

Jeong, Jin-Hyuk, Jaewoon Son, Ji-Hyeon Kwon, Chang-Soo Han, and Chun-Woong Park. "Impact of Different Hydrate Forms of Magnesium Stearate as a Flow Control Agent on the Physical Stability and Inhalation Efficiency of Carrier-Based Formulations." Pharmaceutics 17, no. 6 (2025): 711. https://doi.org/10.3390/pharmaceutics17060711.

Texto completo
Resumen
Objectives: This study aimed to evaluate the impact of the different hydration states of magnesium stearate (Mg.st) anhydrate (AH), monohydrate (MH), and dihydrate (DH) on the aerodynamic performance and stability of carrier-based dry powder inhalation (DPI) formulations using arformoterol and budesonide as model drugs. Methods: DPI formulations were prepared using Inhalac 251 lactose and Mg.st in various hydrated forms. The physicochemical properties of Mg.st were characterized using powder X-ray diffraction, differential scanning calorimetry, Fourier-transform infrared spectroscopy, Karl Fis
Los estilos APA, Harvard, Vancouver, ISO, etc.
11

Terasaki, Jordan, Shawn PE Nishi, Bill T. Ameredes, and Gulshan Sharma. "Arformoterol: rationale for use in chronic obstructive pulmonary disease." Clinical Investigation 4, no. 5 (2014): 429–39. http://dx.doi.org/10.4155/cli.14.32.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
12

*Krishnaphanisri, Ponnekanti, Anusha Addanki, Raj Kamal B., Bhavani Dasari Durga, Reddy Gargula Sumana, and Reddy Karnati Shiva. "A REVIEW-ON METHOD DEVELOPMENT & METHOD VALIDATION BY RP-HPLC FOR ESTIMATION OF ARFORMOTEROL." World Journal of Pharmaceutical Science and Research 4, no. 2 (2025): 1062–70. https://doi.org/10.5281/zenodo.15364947.

Texto completo
Resumen
Arformoterol is a long-acting &beta;<sub>2</sub> adrenoreceptor agonist (LABA) and it is the active (<em>R</em>,<em> R</em>)-(&minus;)enantiomer of formoterol. It was approved for medical use in the United States in October 2006. It is available as a generic medication. Arformoterol is indicated for the maintenance treatment of bronchoconstriction in people with chronic obstructive pulmonary disease (COPD). The purpose of analytical method development is to establish the identity, purity, physical characteristics, and potency of drugs, including the drug&rsquo;s bioavailability and stability.
Los estilos APA, Harvard, Vancouver, ISO, etc.
13

Hanania, Nicola A., James F. Donohue, Harold Nelson, et al. "The Safety and Efficacy of Arformoterol and Formoterol in COPD." COPD: Journal of Chronic Obstructive Pulmonary Disease 7, no. 1 (2010): 17–31. http://dx.doi.org/10.3109/15412550903499498.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
14

Bonasia, Phil, Carrie Cook, Yufei Cheng, and Shaowei Ong. "Compatibility of arformoterol tartrate inhalation solution with three nebulized drugs." Current Medical Research and Opinion 23, no. 10 (2007): 2477–83. http://dx.doi.org/10.1185/030079907x233106.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
15

Miles, Matthew C., James F. Donohue, and Jill A. Ohar. "Nebulized arformoterol: what is its place in the management of COPD?" Therapeutic Advances in Respiratory Disease 7, no. 2 (2012): 81–86. http://dx.doi.org/10.1177/1753465812465784.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
16

Baumgartner, Rudolf A., John P. Hanrahan та Kenneth Sciarappa. "NEBULIZED ARFORMOTEROL, A LONG-ACTING β2 -ADRENERGIC BRONCHODILATOR, IN PATIENTS WITH COPD." Critical Care Medicine 34 (грудень 2006): A95. http://dx.doi.org/10.1097/00003246-200612002-00329.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
17

Hanania, Nicola, James Donohue, Harold Nelson, et al. "LONG-TERM SAFETY AND EFFICACY OF NEBULIZED ARFORMOTEROL IN SUBJECTS WITH COPD." Chest 134, no. 4 (2008): 106P. http://dx.doi.org/10.1378/chest.134.4_meetingabstracts.p106001.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
18

Celli, Bartolome, Maryam Navaie, Vaidyanathan Ganapathy, Zhun Xu, Soojin Cho-Reyes, and Todd Gilmer. "Medication Management Patterns Among Medicare Beneficiaries With COPD Initiating Nebulized Arformoterol Treatment." Chest 152, no. 4 (2017): A775. http://dx.doi.org/10.1016/j.chest.2017.08.806.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
19

Loh, Chee H., James F. Donohue, and Jill A. Ohar. "Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease." Expert Opinion on Drug Safety 14, no. 3 (2015): 463–72. http://dx.doi.org/10.1517/14740338.2015.998196.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
20

Hanrahan, John P., Donna Grogan, Joel Morganroth, Hailong Cheng, and Rudolf Baumgartner. "THE EFFECT OF TWICE-DAILY NEBULIZED ARFORMOTEROL ON QTC IN SUBJECTS WITH COPD." Chest 132, no. 4 (2007): 532C. http://dx.doi.org/10.1378/chest.132.4_meetingabstracts.532c.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
21

Bauer, Andrea, Paul McGlynn, Li Li Bovet, P. Mims, Lisa Curry, and John Hanrahan. "THE INFLUENCE OF BREATHING PATTERN DURING NEBULIZATION ON THE EMITTED DOSE OF ARFORMOTEROL." Chest 132, no. 4 (2007): 616B. http://dx.doi.org/10.1378/chest.132.4_meetingabstracts.616b.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
22

Panettieri, Reynold A., Neil MacIntyre, Michael Sims та ін. "Comparison of the efficacy and safety of arformoterol 15 μg twice daily and arformoterol 30 μg once daily in COPD: A single-dose, multicenter, randomized, modified-blind, two-way crossover study". Clinical Therapeutics 31, № 8 (2009): 1716–23. http://dx.doi.org/10.1016/j.clinthera.2009.08.012.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
23

Ganapathy, Vaidyanathan, and Michael D. Stensland. "Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol." International Journal of Chronic Obstructive Pulmonary Disease Volume 12 (June 2017): 1793–801. http://dx.doi.org/10.2147/copd.s134145.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
24

Madaan, A. "Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease." Drugs of Today 45, no. 1 (2009): 3. http://dx.doi.org/10.1358/dot.2009.45.1.1313983.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
25

Hanrahan, John P., Nicola A. Hanania, William J. Calhoun, Steven A. Sahn, Kenneth Sciarappa, and Rudolf A. Baumgartner. "Effect of Nebulized Arformoterol on Airway Function in COPD: Results from Two Randomized Trials." COPD: Journal of Chronic Obstructive Pulmonary Disease 5, no. 1 (2008): 25–34. http://dx.doi.org/10.1080/15412550701816187.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
26

Hanrahan, J. P., W. B. Smith, K. Sciarappa, W. K. McVicar, and R. A. Baumgartner. "EFFICACY AND SAFETY OF NEBULIZED ARFORMOTEROL IN COPD: A PROSPECTIVE, PHASE III CLINICAL TRIAL." Chest 130, no. 4 (2006): 181S. http://dx.doi.org/10.1378/chest.130.4_meetingabstracts.181s-c.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
27

Stensland, Mike, Vamsi Bollu, and James Donohue. "Hospital Readmissions Among Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Arformoterol or Tiotropium." Chest 148, no. 4 (2015): 714A. http://dx.doi.org/10.1378/chest.2279106.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
28

Tashkin, D. P., J. F. Donohue, D. A. Mahler, et al. "Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD." Respiratory Medicine 103, no. 4 (2009): 516–24. http://dx.doi.org/10.1016/j.rmed.2008.12.014.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
29

Tashkin, Donald, James Donohue, Donald Mahler, et al. "EFFECT OF ARFORMOTEROL TWICE DAILY, TIOTROPIUM ONCE DAILY, AND THEIR COMBINATION IN SUBJECTS WITH COPD." Chest 134, no. 4 (2008): 104P. http://dx.doi.org/10.1378/chest.134.4_meetingabstracts.p104003.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
30

Hinkle, J., J. Hinson, E. Kerwin, et al. "A cumulative dose, safety and tolerability study of arformoterol in pediatric subjects with stable asthma." Pediatric Pulmonology 46, no. 8 (2011): 761–69. http://dx.doi.org/10.1002/ppul.21446.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
31

Celli, Bartolome R., Maryam Navaie, Zhun Xu, Soojin Cho-Reyes, Carole Dembek, and Todd P. Gilmer. "Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment." International Journal of Chronic Obstructive Pulmonary Disease Volume 14 (May 2019): 1019–31. http://dx.doi.org/10.2147/copd.s199251.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
32

Gilmer, Todd P., Bartolome R. Celli, Zhun Xu, Soojin Cho-Reyes, Carole Dembek, and Maryam Navaie. "Predictors of Nebulized Arformoterol Treatment: A Retrospective Analysis of Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease*." COPD: Journal of Chronic Obstructive Pulmonary Disease 16, no. 2 (2019): 140–51. http://dx.doi.org/10.1080/15412555.2019.1618256.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
33

Stensland, Mike, Vamsi Bollu, and James Donohue. "Hospital Readmissions Among Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Arformoterol or Fluticasone/Salmeterol." Chest 148, no. 4 (2015): 716A. http://dx.doi.org/10.1378/chest.2278614.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
34

Bollu, V., L. M. Nelson, V. S. Williams, M. D. Stensland, and D. E. Stull. "Symptom Response Profiles For Patients With Chronic Obstructive Pulmonary Disease Initiating Nebulized Arformoterol Tartrate Or Placebo." Value in Health 17, no. 3 (2014): A170. http://dx.doi.org/10.1016/j.jval.2014.03.995.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
35

Donohue, James F., Nicola A. Hanania, Barry Make, et al. "One-Year Safety and Efficacy Study of Arformoterol Tartrate in Patients With Moderate to Severe COPD." Chest 146, no. 6 (2014): 1531–42. http://dx.doi.org/10.1378/chest.14-0117.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
36

Hanania, Nicola, James Donohue, and Barry Make. "A Large Simple Safety Study of Nebulized Arformoterol Tartrate: Incidence and Risk of Protocol-Defined COPD Exacerbations." Chest 144, no. 4 (2013): 735A. http://dx.doi.org/10.1378/chest.1704476.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
37

&NA;. "Sepracor has launched arformoterol [Brovana] inhalation solution in the US for bronchoconstriction in chronic obstructive pulmonary disorder." Inpharma Weekly &NA;, no. 1584 (2007): 27. http://dx.doi.org/10.2165/00128413-200715840-00083.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
38

Sharma, Sanjay, Ayca Ozol-Godfrey, Thomas Goodin, Barry Price, and Shahin Sanjar. "AN ASSESSMENT OF TIME TO ONSET OF BRONCHODILATION FOLLOWING TREATMENT WITH NEBULIZED ARFORMOTEROL IN PATIENTS WITH COPD." Chest 156, no. 4 (2019): A1622—A1623. http://dx.doi.org/10.1016/j.chest.2019.08.1425.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
39

Bollu, V., R. Carlton, and R. S. Clark. "Health Care Resource Utilization And Rehospitalization Costs Of Nebulized Arformoterol For The Treatment Of Chronic Obstructive Pulmonary Disease." Value in Health 17, no. 3 (2014): A173. http://dx.doi.org/10.1016/j.jval.2014.03.1007.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
40

Bollu, V., Y. J. Chen, and C. Makin. "Treatment Persistence Comparison Between Nebulized Formulations Of Arformoterol And Formoterol In The Treatment Of Chronic Obstructive Pulmonary Disease." Value in Health 17, no. 3 (2014): A177. http://dx.doi.org/10.1016/j.jval.2014.03.1035.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
41

Kharidia, Jahnavi, Charles Fogarty, Craig LaForce, et al. "AN OPEN LABEL STUDY OF ARFORMOTEROL INHALATION SOLUTION AND RACEMIC FORMOTEROL DRY POWDER INHALER IN SUBJECTS WITH COPD." Chest 132, no. 4 (2007): 533B. http://dx.doi.org/10.1378/chest.132.4_meetingabstracts.533b.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
42

Donohue, J. F., N. A. Hanania, K. A. Sciarappa, et al. "Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: A one year evaluation of safety and tolerance." Therapeutic Advances in Respiratory Disease 2, no. 2 (2008): 37–48. http://dx.doi.org/10.1177/1753465808089455.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
43

Das, SibesK, ArunK Bandyopadhyay, Somnath Bhattacharya, Indranil Biswas, and TapanD Bairagya. "A comparative study of efficacy and safety of arformoterol and salbutamol nebulization as rescue therapy in acute non-severe asthma." Indian Journal of Pharmacology 43, no. 4 (2011): 463. http://dx.doi.org/10.4103/0253-7613.83123.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
44

Donohue, James F., Vaidyanathan Ganapathy, Vamsi Bollu, Michael D. Stensland, and Lauren M. Nelson. "Health Status of Patients with Moderate to Severe COPD after Treatment with Nebulized Arformoterol Tartrate or Placebo for 1 Year." Clinical Therapeutics 39, no. 1 (2017): 66–74. http://dx.doi.org/10.1016/j.clinthera.2016.11.021.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
45

Baumgartner, Rudolf A., Nicola A. Hanania, William J. Calhoun, Steven A. Sahn, Kenneth Sciarappa, and John P. Hanrahan. "Nebulized arformoterol in patients with COPD: A 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial." Clinical Therapeutics 29, no. 2 (2007): 261–78. http://dx.doi.org/10.1016/j.clinthera.2007.02.009.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
46

Sun, Chenglong, Jiuming He, Hongbo Wu, et al. "A rapid and sensitive UPLC–MS/MS method for quantitative determination of arformoterol in rat plasma, lung and trachea tissues." Chinese Chemical Letters 29, no. 8 (2018): 1284–86. http://dx.doi.org/10.1016/j.cclet.2018.01.015.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
47

Donohue, James F., Vamsi K. Bollu, Donald E. Stull, et al. "Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial." International Journal of Chronic Obstructive Pulmonary Disease Volume 13 (February 2018): 499–508. http://dx.doi.org/10.2147/copd.s141729.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
48

Nabi, Nusrat, Rishika Agarwal, Himika Mukhopadhyay, et al. "A PHARMACOLOGICAL COMPARATIVE STUDY OF ARFORMOTEROL AND SALBUTAMOL NEBULIZATION IN THE MANAGEMENT OF PATIENTS SUFFERING FROM ACUTE NON-SEVERE BRONCHIAL ASTHMA." Journal of Evolution of Medical and Dental Sciences 6, no. 03 (2017): 215–18. http://dx.doi.org/10.14260/jemds/2017/50.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
49

Sciurba, Frank, Claudia Cote, Kenneth Sciarappa, Elizabeth Goodwin, Lisa Curry, and John Hanrahan. "ASSESSMENT OF PATIENT SYMPTOM AND FUNCTIONING OUTCOMES AMONG COPD SUBJECTS TREATED WITH ARFORMOTEROL OR RACEMIC FORMOTEROL: A 6-MONTH CLINICAL TRIAL." Chest 134, no. 4 (2008): 16P. http://dx.doi.org/10.1378/chest.134.4_meetingabstracts.p16002.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
50

Navaie, Maryam, Bartolome R. Celli, Zhun Xu, Soojin Cho-Reyes, Carole Dembek, and Todd P. Gilmer. "Exacerbations, Health Resource Utilization, and Costs Among Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease Treated with Nebulized Arformoterol Following a Respiratory Event." Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation 6, no. 4 (2019): 297–307. http://dx.doi.org/10.15326/jcopdf.6.4.2019.0127.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
Ofrecemos descuentos en todos los planes premium para autores cuyas obras están incluidas en selecciones literarias temáticas. ¡Contáctenos para obtener un código promocional único!

Pasar a la bibliografía